8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 24, 2007

AmerisourceBergen Corporation

(Exact name of Registrant as specified in its charter)

Delaware	1-16671	23-3079390
(State or Other Jurisdiction of Incorporation or Organization)	Commission File Number	(I.R.S. Employer Identification Number)

1300 Morris Drive Chesterbrook, PA	19087
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (610) 727-7000

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02.  Results of Operations and Financial Condition.

On April 25, 2007, AmerisourceBergen Corporation (the “Registrant”) issued a news release announcing its earnings for the fiscal quarter ended March 31, 2007 and announcing its corresponding earnings conference call. A copy of the news release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 8.01.  Other Events.

On April 24, 2007, the Registrant issued a news release announcing that the U.S. Drug Enforcement Administration has temporarily suspended the Registrant’s Orlando, Florida Distribution Center’s license to distribute controlled substances and listed chemicals. A copy of the news release is filed as Exhibit 99.2 to this report and incorporated herein by reference.

Item 9.01.  Financial Statements and Exhibits.

(d) Exhibits.

99.1 News Release, dated April 25, 2007, regarding Registrant’s earnings for the fiscal quarter ended March 31, 2007.

99.2 News Release, dated April 24, 2007, regarding U.S. Drug Enforcement Administration order.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AMERISOURCEBERGEN CORPORATION
Date: April 25, 2007	By:	/s/ Michael D. DiCandilo
	Name:	Michael D. DiCandilo
	Title:	Executive Vice President and Chief Financial Officer

EX-99.1

Exhibit 99.1

	News Release
	AmerisourceBergen Corporation
	P.O. Box 959
	Valley Forge, PA 19482

Contact:	Michael N. Kilpatric
	610-727-7118
	mkilpatric@amerisourcebergen.com

AMERISOURCEBERGEN REPORTS RECORD QUARTERLY

DILUTED EARNINGS PER SHARE OF $0.68

VALLEY FORGE, PA, April 25, 2007 — AmerisourceBergen Corporation (NYSE:ABC) today reported results for its fiscal second quarter ended March 31, 2007. The following results are presented in accordance with U.S. generally accepted accounting principles (GAAP).

Fiscal Second Quarter Highlights

• Diluted earnings per share from continuing operations of $0.68, up 11 percent.

• Operating revenue of $15.3 billion, up 9 percent.

• Pharmaceutical Distribution operating margin of 1.35 percent, up 8 basis points.

• Cash flow from operations of $423 million, above expectations.

Fiscal First Six Months Highlights

• Diluted earnings per share from continuing operations of $1.30, up 20 percent.

• Operating revenue of $31.0 billion, up 12 percent.

• Pharmaceutical Distribution operating margin of 1.30 percent, up 14 basis points.

• Cash flow from operations of $711 million.

• Capital deployment: $365 million in share repurchases, more than $405 million in acquisitions closed or under agreement, and dividend doubled.

“Our March quarter, historically our strongest, again produced outstanding results, driven by strong performance in our traditional drug and specialty distribution businesses,” said R. David Yost, AmerisourceBergen’s Chief Executive Officer. “Our 9 percent operating revenue growth was in line with expectations. Our excellent earnings per share performance is a result of that revenue growth, expanding margins in distribution, and our disciplined use of cash. During the quarter, we committed more than $260 million in capital with the agreements to acquire Bellco Health and Xcenda. In

News Release

addition, we bought back $35 million of our shares. We retain significant financial flexibility with a strong balance sheet and solid cash position.”

Discussion of Results

AmerisourceBergen’s operating revenue was $15.3 billion in the second quarter of fiscal 2007 compared to $14.0 billion for the same period last year, a 9 percent increase. Bulk deliveries in the quarter increased 5 percent to $1.23 billion from $1.17 billion in last fiscal year’s second quarter.

Consolidated operating income in the quarter increased 12 percent to $220.9 million, primarily due to increased gross margin in the Pharmaceutical Distribution segment. In addition, a $1.8 million gain from settlements of pharmaceutical manufacturer antitrust litigation cases, less $0.1 million of net charges for facility consolidations, employee severance and other costs, had a net positive $1.6 million impact on consolidated operating income in the fiscal 2007 second quarter. In the previous fiscal year’s second quarter, the net positive impact of antitrust litigation settlements and charges for facility consolidations, employee severance and other costs was $5.8 million.

Other income of $5.8 million for the second quarter of fiscal 2006 included $6.5 million relating to the sale of a small investment and an eminent domain settlement.

The effective tax rate in the second quarter of fiscal 2007 was 38.5 percent up from 34.5 percent in the previous fiscal year’s second quarter, which included $5.5 million of favorable tax adjustments. The Company expects the tax rate for the remaining quarters in fiscal 2007 to be between 37 percent and 38 percent.

Diluted earnings per share from continuing operations were $0.68 in the second quarter of fiscal 2007, compared to $0.61 in the previous fiscal year’s second quarter, an 11 percent increase. Included in the results for the second quarter of fiscal 2007 is a gain from the antitrust litigation settlements as well as a charges for facility consolidations, employee severance and other costs, which resulted in a charge, net of tax, of $0.3 million or zero cents per diluted share.

Special items in the second quarter of fiscal 2006, which included gains from antitrust litigation settlements, an investment sale and an eminent domain settlement, and the tax adjustments, less the charges for facility consolidations, employee severance and other costs, resulted in a benefit, net of tax, of $13.6 million or $0.06 per diluted share.

Diluted average shares outstanding for the second quarter of fiscal year 2007 were 191.8 million, down 19 million from the previous fiscal year’s second quarter due to share repurchases, net of option exercises.

2

News Release

For the first six months of fiscal 2007, AmerisourceBergen’s operating revenue was $31.0 billion compared to $27.6 billion for the same period last year, a 12 percent increase. Bulk deliveries in the first half of the fiscal year decreased 1 percent to $2.3 billion.

Consolidated operating income in the first six months of the fiscal year increased 18 percent to $429.8 million due to operating income growth in the Pharmaceutical Distribution segment.

For the first six months of fiscal 2007 diluted earnings per share from continuing operations were $1.30, compared to $1.08 in the previous year’s first six months, a 20 percent increase.

“For the fiscal 2007 second quarter, excellent operating performance in the Pharmaceutical Distribution segment more than offset the lower than expected performance in the PharMerica segment,” said Kurt J. Hilzinger, AmerisourceBergen’s President and Chief Operating Officer.

“Our Drug Corporation, which provides pharmaceutical distribution and related services to pharmacies, led distribution performance in the quarter with solid margin expansion. Performance under our fee-for-service agreements, continued strong sales of generic pharmaceuticals, and price appreciation were gross margin drivers in the quarter. Benefits from Optimiz^®, our program to enhance the efficiency of our distribution center network, continued to improve our cost structure. Our pending acquisition of Bellco Health, a pharmaceutical distributor, is expected to enhance our capability in the distribution segment.

“With operating revenues up 27 percent, our Specialty Group, which focuses on the distribution of specialty pharmaceuticals to physicians and the services that support that market, continued its strong growth. Its market-leading oncology businesses as well as other distribution businesses to physicians continue to drive growth faster than the overall pharmaceutical market.

“Our Packaging Group continued to perform well. In the quarter, Anderson Packaging began packaging five new products for branded manufacturers and American Health Packaging launched 11 new proprietary generic product offerings for various customers. We continued to invest in this business during the quarter with the approval of a new 260,000-square-foot facility for Anderson in Rockford, Illinois.

“Our PharMerica segment earnings lagged in the second quarter due to lower than expected performance in the PMSI workers’ compensation business, primarily because of increased competitive pressure on customer pricing. The Long Term Care business grew revenues 5 percent in the quarter, and remains on track to meet our expectations for the fiscal year.”

3

News Release

Segment Review

AmerisourceBergen operates in two segments, Pharmaceutical Distribution and PharMerica. Pharmaceutical Distribution includes the operations of AmerisourceBergen Drug Corporation (ABDC), Specialty Group (ABSG) and Packaging Group (ABPG), and PharMerica includes the PharMerica Long Term Care (LTC) institutional pharmacy business and PMSI, the workers’ compensation business. Intersegment sales of $231.6 million in the second quarter of fiscal 2007 from AmerisourceBergen Drug Corporation to PharMerica, which are included in the Pharmaceutical Distribution segment’s operating revenue, are eliminated for consolidated reporting purposes.

Pharmaceutical Distribution Segment

Operating revenue of $15.1 billion in the second quarter of fiscal 2007 was up 9 percent compared to the same quarter in the previous fiscal year as above market distribution growth in ABSG drove operating revenues to the high end of overall market growth. Pharmaceutical Distribution customer mix in the second quarter of fiscal 2007 was 62 percent institutional and 38 percent retail.

For the segment, gross profit as a percentage of operating revenue in the second quarter of fiscal 2007 was 3.23 percent compared to 3.16 percent in the same period in the prior fiscal year. The increase was driven by margin expansion in ABDC as a result of strong performance under fee-for-service agreements, generic sales growth that was above overall market growth, and price appreciation. This offset a decline in ABSG’s gross margin due to its business mix, as its lower margin distribution businesses grew faster than its higher margin service businesses. Operating expenses as a percentage of operating revenue for the segment in the fiscal 2007 second quarter were 1.87 percent, down from 1.89 percent in the prior year’s second quarter, reflecting continuing operating leverage.

Segment operating income for the fiscal 2007 second quarter was $203.9 million, a 16 percent increase over the same period in fiscal 2006. Operating income as a percentage of operating revenue in the second quarter of 2007 was 1.35 percent, up eight basis points over the same quarter last fiscal year.

PharMerica

PharMerica’s operating revenue for the second quarter of fiscal 2007 was $431.4 million, compared with $412.7 million in the previous year’s second quarter, up 5 percent due to the growth in LTC. In the second quarter of fiscal 2007, LTC operating revenues were $316.8 million and PMSI operating revenues were $114.6 million. Operating income for the second quarter of fiscal 2007 was $15.4 million, down from the same quarter last fiscal year, with LTC contributing $6.8 million and PMSI contributing $8.6 million. Operating income as a percentage of revenue was 3.56 percent in the

4

News Release

second quarter of fiscal 2007, down from the 3.92 percent in last year’s second quarter due to PMSI’s relatively flat revenue growth and competitive pressures.

Looking Ahead

“In April 2007, we received an antitrust litigation settlement that will provide a gain of $0.06 per diluted share in the third fiscal quarter of 2007, which net of anticipated special charges over the last half of the fiscal year, is expected to provide a benefit of $0.05 per diluted share in the 2007 fiscal year,” said Yost. “As a result, we are raising our GAAP diluted earnings per share expectations for fiscal 2007 by $0.05 to a range of $2.50 to $2.65 from a range of $2.45 to $2.60. The PharMerica Long-Term Care business, which the Company continues to expect to spin off on a tax-free basis to our shareholders by the end of June 2007, continues to represent $0.09 to $0.11 of our earnings expectations for all of fiscal year 2007. Our diluted earnings per share guidance for fiscal 2007 continues to assume operating revenue growth of 9 percent to 11 percent and reflects operating margin expansion in the high single-digit basis point range for the Pharmaceutical Distribution segment.”

“With our operating cash generation coming in ahead of expectations at the end of six months, we are raising our expectation for free cash flow in fiscal year 2007 by $150 million to a range of $575 million to $650 million from the previous range of $425 million to $500 million. Capital expenditures, which are included in the free cash flow expectation, remain unchanged in the $100 million to $125 million range,” continued Yost. “We also continue to expect to repurchase $450 million to $500 million of our common shares during fiscal 2007.”

Conference Call

The Company will host a conference call to discuss its results at 11:00 a.m. Eastern Daylight Time on April 25, 2007. Participating in the conference call will be: R. David Yost, Chief Executive Officer; Kurt J. Hilzinger, President and Chief Operating Officer; and Michael D. DiCandilo, Executive Vice President and Chief Financial Officer.

To access the live conference call via telephone:

Dial in: (612) 288-0337, no access code required.

To access the live webcast:

Go to the Quarterly Webcasts section on the Investor Relations page at http://www.amerisourcebergen.com.

5

News Release

A replay of the telephone call and webcast will be available from 2:30 p.m. April 25, 2007 until 11:59 p.m. May 2, 2007. The Webcast replay will be available for 30 days.

To access the replay via telephone:

Dial in:	800-475-6701 from within the U.S., access code: 869797
	(320) 365-3844 from outside the U.S., access code: 869797

To access the archived webcast:

Go to the Quarterly Webcasts section on the Investor Relations page at http://www.amerisourcebergen.com.

About AmerisourceBergen

AmerisourceBergen (NYSE:ABC) is one of the world’s largest pharmaceutical services companies serving the United States, Canada and selected global markets. Servicing both pharmaceutical manufacturers and healthcare providers in the pharmaceutical supply channel, the Company provides drug distribution and related services designed to reduce costs and improve patient outcomes. AmerisourceBergen’s service solutions range from pharmacy automation and pharmaceutical packaging to pharmacy services for skilled nursing and assisted living facilities, reimbursement and pharmaceutical consulting services, and physician education. With more than $64 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 13,000 people. AmerisourceBergen is ranked #29 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com.

Forward-Looking Statements

This news release may contain certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in any forward-looking statements: competitive pressures; the loss of one or more key customer or supplier relationships; customer defaults or insolvencies; changes in customer mix; supplier defaults or insolvencies; changes in pharmaceutical manufacturers’ pricing and distribution policies or practices; adverse resolution of any contract or other disputes with customers (including departments and agencies of the U.S. Government) or suppliers; regulatory changes (including increased government regulation of the pharmaceutical supply channel); changes in U.S. government policies (including reimbursement changes arising from federal legislation, including the Medicare Modernization Act and the Deficit Reduction Act of 2005); changes in regulatory or private medical guidelines and/or reimbursement practices for the pharmaceuticals we distribute; price inflation in branded pharmaceuticals and price deflation in generics; declines in the amounts of market share rebates offered by pharmaceutical manufacturers to the PharMerica Long-Term Care business, declines in the amounts of rebates that the PharMerica Long-Term Care business can retain, and/or the inability of the business to offset the rebate reductions that have already occurred or any rebate reductions that may occur in the future; any disruption to or other adverse effects upon the PharMerica Long-Term Care business caused by the announcement of the Company’s agreement to combine the PharMerica Long-Term Care business with the institutional pharmacy business of Kindred Healthcare, Inc. into a new public company that will be owned 50% by the Company’s shareholders (the “PharMerica LTC Transaction”); the inability of the Company to successfully complete

6

News Release

the PharMerica LTC Transaction; fluctuations in market interest rates; operational or control issues arising from the Company’s outsourcing of information technology activities; success of integration, restructuring or systems initiatives; fluctuations in the U.S. dollar—Canadian dollar exchange rate and other foreign exchange rates; economic, business, competitive and/or regulatory developments in Canada, the United Kingdom and elsewhere outside of the United States; acquisition of businesses that do not perform as we expect or that are difficult for us to integrate or control; changes in tax legislation or adverse resolution of challenges to our tax positions; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the business of the Company generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors) in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2006 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act of 1934.

###

7

AMERISOURCEBERGEN CORPORATION

FINANCIAL SUMMARY

(In thousands, except per share data)

(unaudited)

	Three Months Ended March 31, 2007		% of Operating Revenue		Three Months Ended March 31, 2006			% of Operating Revenue		% Change
Revenue:
Operating revenue	$	15,283,761	100.00	%	$	14,049,175		100.00	%	9	%
Bulk deliveries to customer warehouses		1,228,780				1,171,504				5	%
Total revenue		16,512,541				15,220,679				8	%
Cost of goods sold		15,906,098				14,659,916				9	%
Gross profit		606,443	3.97	%		560,763		3.99	%	8	%
Operating expenses:
Distribution, selling and administrative		363,367	2.38	%		339,113		2.41	%	7	%
Depreciation and amortization		22,049	0.14	%		20,149		0.14	%	9	%
Facility consolidations, employee severance, and other		135	—			3,577		0.03	%	-96	%
Operating income		220,892	1.45	%		197,924		1.41	%	12	%
Other loss (income)		376	—			(5,826	)	-0.04	%	-106	%
Interest expense, net		9,889	0.06	%		7,344		0.05	%	35	%
Income from continuing operations before income taxes		210,627	1.38	%		196,406		1.40	%	7	%
Income taxes		81,131	0.53	%		67,816		0.48	%	20	%
Income from continuing operations		129,496	0.85	%		128,590		0.92	%	1	%
Income from discontinued operations, net of tax		—				(411	)
Net income	$	129,496	0.85	%	$	129,001		0.92	%	—
Earnings per share:
Basic
Continuing operations	$	0.69			$	0.62				11	%
Discontinued operations		—				—
Net income	$	0.69			$	0.62				11	%
Diluted
Continuing operations	$	0.68			$	0.61				11	%
Discontinued operations		—				—
Net income	$	0.68			$	0.61				11	%
Weighted average common shares outstanding:
Basic		188,772				208,050
Diluted		191,797				210,771

AMERISOURCEBERGEN CORPORATION

FINANCIAL SUMMARY

(In thousands, except per share data)

(unaudited)

	Six Months Ended March 31, 2007		% of Operating Revenue		Six Months Ended March 31, 2006			% of Operating Revenue		% Change
Revenue:
Operating revenue	$	30,980,300	100.00	%	$	27,585,029		100.00	%	12	%
Bulk deliveries to customer warehouses		2,257,634				2,288,797				-1	%
Total revenue		33,237,934				29,873,826				11	%
Cost of goods sold		32,036,848				28,784,685				11	%
Gross profit		1,201,086	3.88	%		1,089,141		3.95	%	10	%
Operating expenses:
Distribution, selling and administrative		720,328	2.33	%		670,972		2.43	%	7	%
Depreciation and amortization		44,849	0.14	%		41,236		0.15	%	9	%
Facility consolidations, employee severance, and other		6,158	0.02	%		12,404		0.04	%	-50	%
Operating income		429,751	1.39	%		364,529		1.32	%	18	%
Other loss (income)		442	—			(5,043	)	-0.02	%	-109	%
Interest expense, net		18,032	0.06	%		13,856		0.05	%	30	%
Income from continuing operations before income taxes		411,277	1.33	%		355,716		1.29	%	16	%
Income taxes		159,594	0.52	%		129,150		0.47	%	24	%
Income from continuing operations		251,683	0.81	%		226,566		0.82	%	11	%
Loss from discontinued operations, net of tax		—				298
Net income	$	251,683	0.81	%	$	226,268		0.82	%	11	%
Earnings per share:
Basic
Continuing operations	$	1.32			$	1.09				21	%
Discontinued operations		—				—
Net income	$	1.32			$	1.09				21	%
Diluted
Continuing operations	$	1.30			$	1.08				20	%
Discontinued operations		—				—
Rounding		—				(0.01	)
Net income	$	1.30			$	1.07				21	%
Weighted average common shares outstanding:
Basic		190,607				208,160
Diluted		193,409				210,570

AMERISOURCEBERGEN CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

	March 31, 2007		September 30, 2006
ASSETS
Current assets:
Cash and cash equivalents	$	778,382	$	1,261,268
Short-term investment securities available-for-sale		830,455		67,840
Accounts receivable, net		3,633,713		3,427,139
Merchandise inventories		4,602,195		4,422,055
Prepaid expenses and other		30,065		32,105
Total current assets		9,874,810		9,210,407
Property and equipment, net		525,572		509,746
Other long-term assets		3,186,390		3,063,767
Total assets	$	13,586,772	$	12,783,920
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	7,301,994	$	6,499,264
Current portion of long-term debt		833		1,560
Other current liabilities		888,116		958,364
Total current liabilities		8,190,943		7,459,188
Long-term debt, less current portion		1,199,138		1,093,931
Other long-term liabilities		102,007		89,644
Stockholders’ equity		4,094,684		4,141,157
Total liabilities and stockholders’ equity	$	13,586,772	$	12,783,920

AMERISOURCEBERGEN CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

	Six Months Ended March 31, 2007			Six Months Ended March 31, 2006
Operating Activities:
Net income	$	251,683		$	226,268
Adjustments to reconcile net income to net cash provided by operating activities		106,168			106,437
Changes in operating assets and liabilities		352,956			369,933
Net cash provided by operating activities		710,807			702,638
Investing Activities:
Capital expenditures		(57,397	)		(60,149	)
Cost of acquired companies, net of cash acquired		(144,649	)		(238,427	)
Proceeds from sales of property and equipment		4,103			2,199
Proceeds from sale-leaseback transactions		—			28,143
Proceeds from sale of equity investment and eminent domain settlement		—			7,582
Net short-term investment activity		(762,615	)		(515,987	)
Net cash used in investing activities		(960,558	)		(776,639	)
Financing Activities:
Net borrowings		107,802			124,916
Deferred financing costs and other		(1,920	)		(992	)
Purchases of common stock		(396,193	)		(132,226	)
Exercises of stock options		77,290			97,804
Cash dividends on common stock		(19,193	)		(10,464	)
Purchases of common stock for employee stock purchase plan		(921	)		(1,037	)
Net cash (used in) provided by financing activities		(233,135	)		78,001
(Decrease) increase in cash and cash equivalents		(482,886	)		4,000
Cash and cash equivalents at beginning of period		1,261,268			966,553
Cash and cash equivalents at end of period	$	778,382		$	970,553

AMERISOURCEBERGEN CORPORATION

SUMMARY SEGMENT INFORMATION

(dollars in thousands)

(unaudited)

	Three Months Ended March 31,
Operating Revenue	2007			2006			% Change
Pharmaceutical Distribution	$	15,084,048		$	13,877,560		9	%
PharMerica		431,360			412,685		5	%
Intersegment eliminations		(231,647	)		(241,070	)	-4	%
Operating revenue	$	15,283,761		$	14,049,175		9	%
	Three Months Ended March 31,
Operating Income	2007			2006			% Change
Pharmaceutical Distribution	$	203,910		$	175,951		16	%
PharMerica		15,364			16,171		-5	%
Facility consolidations, employee severance, and other		(135	)		(3,577	)	-96	%
Gain on antitrust litigation settlements		1,753			9,379		-81	%
Operating income	$	220,892		$	197,924		12	%
Percentages of operating revenue:
Pharmaceutical Distribution
Gross profit		3.23	%		3.16	%
Operating expenses		1.87	%		1.89	%
Operating income		1.35	%		1.27	%
PharMerica
Gross profit		27.37	%		27.48	%
Operating expenses		23.81	%		23.56	%
Operating income		3.56	%		3.92	%
AmerisourceBergen Corporation
Gross profit		3.97	%		3.99	%
Operating expenses		2.52	%		2.58	%
Operating income		1.45	%		1.41	%

AMERISOURCEBERGEN CORPORATION

SUMMARY SEGMENT INFORMATION

(dollars in thousands)

(unaudited)

	Six Months Ended March 31,
Operating Revenue	2007			2006			% Change
Pharmaceutical Distribution	$	30,577,171		$	27,225,713		12	%
PharMerica		867,245			821,943		6	%
Intersegment eliminations		(464,116	)		(462,627	)	—
Operating revenue	$	30,980,300		$	27,585,029		12	%
	Six Months Ended March 31,
Operating Income	2007			2006			% Change
Pharmaceutical Distribution	$	398,043		$	314,827		26	%
PharMerica		34,223			34,678		-1	%
Facility consolidations, employee severance, and other		(6,158	)		(12,404	)	-50	%
Gain on antitrust litigation settlements		3,643			27,428		-87	%
Operating income	$	429,751		$	364,529		18	%
Percentages of operating revenue:
Pharmaceutical Distribution
Gross profit		3.13	%		3.07	%
Operating expenses		1.83	%		1.91	%
Operating income		1.30	%		1.16	%
PharMerica
Gross profit		27.77	%		27.64	%
Operating expenses		23.83	%		23.42	%
Operating income		3.95	%		4.22	%
AmerisourceBergen Corporation
Gross profit		3.88	%		3.95	%
Operating expenses		2.49	%		2.63	%
Operating income		1.39	%		1.32	%

AMERISOURCEBERGEN CORPORATION

EARNINGS PER SHARE

(In thousands, except per share data)

(unaudited)

Basic earnings per share is computed on the basis of the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed on the basis of the weighted average number of shares of common stock outstanding during the periods presented plus the dilutive effect of stock options and restricted stock.

	Three Months Ended March 31,				Six Months Ended March 31,
	2007		2006		2007		2006
Income from continuing operations	$	129,496	$	128,590	$	251,683	$	226,566
Weighted average common shares outstanding—basic		188,772		208,050		190,607		208,160
Effect of dilutive securities—stock options and restricted stock		3,025		2,721		2,802		2,410
Weighted average common shares outstanding—diluted		191,797		210,771		193,409		210,570
Earnings per share:
Basic
Continuing operations	$	0.69	$	0.62	$	1.32	$	1.09
Discontinued operations		—		—		—		—
Net income	$	0.69	$	0.62	$	1.32	$	1.09
Diluted
Continuing operations	$	0.68	$	0.61	$	1.30	$	1.08
Discontinued operations		—		—		—		—
Rounding		—		—		—		(0.01	)
Net income	$	0.68	$	0.61	$	1.30	$	1.07

EX-99.2

Exhibit 99.2

	News Release
	AmerisourceBergen Corporation
	P.O. Box 959
	Valley Forge, PA 19482

Contact:	Michael N. Kilpatric
	610-727-7118
	mkilpatric@amerisourcebergen.com

AMERISOURCEBERGEN RECEIVES DEA ORDER TO

TEMPORARILY HALT DISTRIBUTION OF CONTROLLED SUBSTANCES

FROM ITS ORLANDO, FLORIDA FACILITY

VALLEY FORGE, PA, April 24, 2007 — AmerisourceBergen Corporation (NYSE:ABC) today announced that the U.S. Drug Enforcement Administration (DEA) has temporarily suspended the Orlando, Florida Distribution Center’s (DC) license to distribute DEA controlled substances and listed chemicals. The temporary suspension affects only the Orlando DC and only DEA controlled items. The action may impact approximately 1,400 pharmacy customers in Florida. In the event this temporary suspension is not quickly resolved, alternative arrangements will be made for customers served by the Orlando Distribution Center, so they will not be inconvenienced.

The DEA asserts that AmerisourceBergen did not maintain effective controls against diversion of controlled substances, specifically hydrocodone, to four internet pharmacies from January 1, 2006 through January 31, 2007.

Historically, AmerisourceBergen has proactively cooperated with the DEA in preventing diversion of hydrocodone and other controlled substances, and will fully cooperate with the agency in resolving the temporary suspension.

The Company has a diversion program and a DEA-approved suspicious-order monitoring program in place to identify customers who are suspected of inappropriately selling products sold to them by AmerisourceBergen. All of the Orlando Distribution Center’s DEA audits, the most recent within the last year, were passed with no deficiencies found. AmerisourceBergen is not doing business with any of the four customers cited by the DEA, and all of the pharmacies mentioned by the agency held active DEA licenses to sell controlled substances at the time AmerisourceBergen sold product to them.

News Release

About AmerisourceBergen

AmerisourceBergen (NYSE:ABC) is one of the world’s largest pharmaceutical services companies serving the United States, Canada and selected global markets. Servicing both pharmaceutical manufacturers and healthcare providers in the pharmaceutical supply channel, the Company provides drug distribution and related services designed to reduce costs and improve patient outcomes. AmerisourceBergen’s service solutions range from pharmacy automation and pharmaceutical packaging to pharmacy services for skilled nursing and assisted living facilities, reimbursement and pharmaceutical consulting services, and physician education. With more than $64 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 13,000 people. AmerisourceBergen is ranked #29 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com.

Forward-Looking Statements

This news release may contain certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in any forward-looking statements: competitive pressures; the loss of one or more key customer or supplier relationships; customer defaults or insolvencies; changes in customer mix; supplier defaults or insolvencies; changes in pharmaceutical manufacturers’ pricing and distribution policies or practices; adverse resolution of any contract or other disputes with customers (including departments and agencies of the U.S. Government) or suppliers; regulatory changes (including increased government regulation of the pharmaceutical supply channel); changes in U.S. government policies (including reimbursement changes arising from federal legislation, including the Medicare Modernization Act and the Deficit Reduction Act of 2005); changes in regulatory or private medical guidelines and/or reimbursement practices for the pharmaceuticals we distribute; price inflation in branded pharmaceuticals and price deflation in generics; declines in the amounts of market share rebates offered by pharmaceutical manufacturers to the PharMerica Long-Term Care business, declines in the amounts of rebates that the PharMerica Long-Term Care business can retain, and/or the inability of the business to offset the rebate reductions that have already occurred or any rebate reductions that may occur in the future; any disruption to or other adverse effects upon the PharMerica Long-Term Care business caused by the announcement of the Company’s agreement to combine the PharMerica Long-Term Care business with the institutional pharmacy business of Kindred Healthcare, Inc. into a new public company that will be owned 50% by the Company’s shareholders (the “PharMerica LTC Transaction”); the inability of the Company to successfully complete the PharMerica LTC Transaction; fluctuations in market interest rates; operational or control issues arising from the Company’s outsourcing of information technology activities; success of integration, restructuring or systems initiatives; fluctuations in the U.S. dollar—Canadian dollar exchange rate and other foreign exchange rates; economic, business, competitive and/or regulatory developments in Canada, the United Kingdom and elsewhere outside of the United States; acquisition of businesses that do not perform as we expect or that are difficult for us to integrate or control; changes in tax legislation or adverse resolution of challenges to our tax positions; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the business of the Company generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors) in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2006 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act of 1934.

###

2